Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915067 · ClinicalTrials.gov registry record · Phase 2
BOTOX® for the Treatment of Platysma Prominence
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT03915067 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 171 participants.
The verdict
NCT03915067, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
Interventions
- DRUG Placebo
- DRUG BOTOX® purified neurotoxin complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915067
The ClinicalTrials.gov registry entry for NCT03915067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03915067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03915067 about?
NCT03915067 is a clinical study titled "BOTOX® for the Treatment of Platysma Prominence". To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
What is the current status of trial NCT03915067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2019-04-23. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT03915067?
The interventions under investigation include: Placebo (DRUG), BOTOX® purified neurotoxin complex (DRUG).
Who is sponsoring clinical trial NCT03915067?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.